NASDAQ:IRMD - Nasdaq - US46266A1097 - Common Stock - Currency: USD
IRADIMED CORP
NASDAQ:IRMD (2/5/2025, 8:07:39 PM)
After market: 62.67 0 (0%)62.67
+1.44 (+2.35%)
The current stock price of IRMD is 62.67 USD. In the past month the price increased by 10.94%. In the past year, price increased by 44.6%.
Why the quality investor may take a look at IRADIMED CORP (NASDAQ:IRMD).
WINTER SPRINGS, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 fourth...
Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 millionReports preliminary full-year 2024 revenue in...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.28 | 229.05B | ||
ISRG | INTUITIVE SURGICAL INC | 80.61 | 210.47B | ||
BSX | BOSTON SCIENTIFIC CORP | 44.48 | 154.71B | ||
SYK | STRYKER CORP | 32.74 | 152.14B | ||
MDT | MEDTRONIC PLC | 17.46 | 117.57B | ||
BDX | BECTON DICKINSON AND CO | 18.62 | 71.07B | ||
EW | EDWARDS LIFESCIENCES CORP | 27 | 42.52B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.66 | 39.83B | ||
IDXX | IDEXX LABORATORIES INC | 41.65 | 38.36B | ||
RMD | RESMED INC | 27.44 | 35.61B | ||
DXCM | DEXCOM INC | 52.22 | 34.68B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 20.62 | 25.78B |
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. The company is headquartered in Winter Springs, Florida and currently employs 148 full-time employees. The company went IPO on 2014-07-16. Its MRidium 3860+ MRI Compatible IV infusion pump system provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The firm sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gausses.
IRADIMED CORP
1025 Willa Springs Dr.
Winter Springs FLORIDA 32708 US
CEO: Roger Susi
Employees: 148
Company Website: http://www.iradimed.com/
Investor Relations: https://www.iradimed.com/investors/events
Phone: 14076778022
The current stock price of IRMD is 62.67 USD.
The exchange symbol of IRADIMED CORP is IRMD and it is listed on the Nasdaq exchange.
IRMD stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for IRMD, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of IRMD.
IRMD has a dividend yield of 0.99%. The yearly dividend amount is currently 1.05.
IRMD will report earnings on 2025-02-13, after the market close.
The PE ratio for IRMD is 39.17. This is based on the reported non-GAAP earnings per share of 1.6 and the current share price of 62.67 USD.
The outstanding short interest for IRMD is 1.86% of its float.
ChartMill assigns a technical rating of 10 / 10 to IRMD. When comparing the yearly performance of all stocks, IRMD is one of the better performing stocks in the market, outperforming 87.53% of all stocks.
ChartMill assigns a fundamental rating of 8 / 10 to IRMD. Both the health and profitability get an excellent rating, making IRMD a very profitable company, without any liquidiy or solvency issues.
Over the last trailing twelve months IRMD reported a non-GAAP Earnings per Share(EPS) of 1.6. The EPS increased by 13.48% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 26.12% | ||
ROA | 19.76% | ||
ROE | 22.33% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to IRMD. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 14.41% and a revenue growth 11.59% for IRMD